PRIME vs. ILAP: A Comparison of EMA & MHRA Expedited Pathways
PRIME vs. ILAP: Comparing the EMA and MHRA’s Expedited Pathways
For pharma and biotech companies, speed to market is critical. Both the European Medicines Agency (EMA) and the UK’s MHRA offer powerful expedited pathways to support the development and review of promising new medicines.
These schemes (PRIME from the EMA and ILAP from the MHRA) are both designed to help patients get access to new treatments faster. However, they are not the same. They have different eligibility criteria, different benefits, and require different strategic approaches. This article compares the two, side-by-side, to help you decide which pathway is right for your product.
PRIME vs. ILAP: At-a-Glance Comparison
|
|
|
|
Full Name |
PRIority MEdicines |
Innovative Licensing & Access Pathway |
|
Agency |
EMA (European Union) |
MHRA (United Kingdom) |
|
Core Goal |
Support development of medicines for an unmet medical need. |
Accelerate the entire product lifecycle for innovative products. |
|
Key BenefitKey Benefit |
Enhanced Scientific Advice & potential for Accelerated Assessment (150 days). |
Access to a “toolkit” including the Target Development Profile (TDP), a “living” roadmap for development. |
|
“The Badge” |
PRIME Designation |
Innovation Passport |
|
Key Eligibility |
Must show robust early data (non-clinical/clinical) demonstrating a major therapeutic advantage. |
Must have at least one innovative feature (e.g., new active substance, novel drug delivery, AI development). |
|
Who Can Apply |
Primarily aimed at SMEs and academia, but open to all. |
Open to all, including large pharma. |
A Deeper Look: The EMA’s PRIME Scheme
The PRIME scheme is all about one thing: unmet medical need. Its primary benefit is enhanced dialogue with the EMA. This includes appointing an EMA rapporteur and multidisciplinary meetings with the Scientific Advice Working Party (SAWP) to ensure your development plan is robust for the final MAA.
Who Should Apply for PRIME?
You should apply for PRIME if you have strong, convincing early data (e.g., compelling non-clinical data or early clinical proof-of-concept) that your product will offer a major therapeutic advantage over existing treatments. It is ideal for truly novel therapies in areas with no good options.
A Deeper Look: The MHRA’s ILAP
ILAP is broader than PRIME. It’s not just an “accelerated assessment” but a complete toolkit to support the entire development pathway. The key benefit is gaining the “Innovation Passport”, which unlocks the Target Development Profile (TDP).
What is the Target Development Profile (TDP)?
The TDP is a ‘living document’ created in collaboration with the MHRA and its partners (like NICE in England). It outlines the specific development activities, trial endpoints, and data needed for approval and reimbursement. It’s a dynamic roadmap that can be updated as new data emerges, providing unparalleled regulatory flexibility.
Strategic Conclusion: Can You (and Should You) Apply for Both?
Yes, you can apply for both. The schemes are entirely independent and non-mutually exclusive. In fact, for a strong product, a dual-track strategy is often ideal.
- Use PRIME to validate your EU strategy and get enhanced scientific advice from the EMA.
- Use ILAP to create a flexible, efficient UK-specific development and access plan (the TDP), which can run in parallel.
- The Challenge: While you can apply for both, it requires resources to manage two separate, high-intensity regulatory interactions.